Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.68 |
| ▸ | BLVRB | P30043 | 1/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | RAB9A | P51151 | 4/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.57 |
| ▸ | GRM5 | P41594 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL60640 | 0.92 | NPC1 (0.71) | MAOABLVRBHDAC6NPC1RAB9A | |
| SCHEMBL12171924 | 0.92 | NPC1 (0.71) | MAOABLVRBHDAC6NPC1RAB9A | |
| SCHEMBL60333 | 0.89 | MAOA (0.68) | MAOABLVRBHDAC6NPC1RAB9A | |
| SCHEMBL60427 | 0.87 | NPC1 (0.76) | MAOABLVRBHDAC6NPC1RAB9A | |
| SCHEMBL4875653 | 0.86 | NPC1 (0.67) | MAOABLVRBHDAC6NPC1RAB9A | |
| SCHEMBL59154 | 0.84 | MAOA (0.78) | MAOABLVRBHDAC6NPC1RAB9A | |
| SCHEMBL17336565 | 0.84 | NPC1 (0.72) | MAOABLVRBHDAC6NPC1RAB9A | |
| SCHEMBL59247 | 0.84 | RAB9A (0.72) | MAOABLVRBHDAC6NPC1RAB9A | |
| SCHEMBL12171569 | 0.84 | NPC1 (0.76) | MAOABLVRBHDAC6NPC1RAB9A | |
| SCHEMBL60051 | 0.84 | NPC1 (0.72) | MAOABLVRBHDAC6NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419991-B2 | Treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | PTC THERAPEUTICS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20060148864-A1 | Treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | PTC THERAPEUTICS, INC. | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148864-A1 | Treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | UPF1, PABPC1, PABPC4 | MAOA 3474/4885BLVRB 2415/4885HDAC6 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.